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Abstract  
Replacement of pancreatic β-cells through deceased donor islet transplantation is a proven 
therapy for preventing recurrent life-threatening hypoglycemia in type 1 diabetes. Although 
near-normal glucose levels and insulin independence can be maintained for many years 
following successful islet transplantation, restoration of normal functional β-cell mass has 
remained elusive. It has recently been proposed that dedifferentiation / plasticity towards 
other endocrine phenotypes may play an important role in stress-induced β-cell dysfunction 
in type 2 diabetes.   Here we report loss of end-differentiated β-cell phenotype in two 
intraportal islet allotransplant recipients. Despite excellent graft function and sustained 
insulin independence, all examined insulin-positive cells had lost expression of the end-
differentiation marker, urocortin-3, or appeared to co-express the α-cell marker, glucagon. In 
contrast, no insulin
+
 / urocortin-3
-
 cells were seen in non-diabetic deceased donor control 
pancreatic islets.  Loss of end-differentiated phenotype may facilitate β-cell survival during 
the stresses associated with islet isolation and culture, in addition to sustained hypoxia 
following engraftment. As further refinements in islet isolation and culture are made in 
parallel with exploration of alternative β-cell sources, graft sites and ultimately fully-
vascularised bioengineered insulin-secreting microtissues, differentiation status 
immunostaining provides a novel tool to assess whether fully mature β-cell phenotype has 
been maintained. 
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Introduction  
Following reproducible attainment of insulin independence through the Edmonton protocol
1
, 
islet transplantation has become an established therapy for prevention of recurrent life-
threatening severe hypoglycemia in type 1 diabetes
2
. Although optimal islet grafts can restore 
non-diabetic glucose levels without adjuvant glucose-lowering therapy, detailed metabolic 
testing has revealed incomplete restoration of normal functional β-cell mass
3
. This is in 
contrast to vascularised whole pancreas transplant where normalisation of β-cell secretory 
capacity has been confirmed
4
. During pancreas development co-expression of insulin and the 
peptide hormone urocortin-3 is a phenotypic marker of full β-cell maturation
5
. Maintenance 
of β-cell urocortin-3 expression is required for physiological regulation of insulin secretion, 
with urocortin-3 null mice having deficient insulin secretion during periods of high glucose
6
. 
Beta-cell dysfunction, defined by loss of mature end-differentiated phenotypic markers, 
including urocortin-3
7
, and expression of non-β-cell proteins, including glucagon
8
, has 
recently been postulated as an important contributor to impaired insulin secretion in type 2 
diabetes
9,10
. We report abnormal β-cell phenotypes in two islet transplant recipients despite 
excellent graft function. 
 
Methods 
Peripheral and central tissue blocks of right and left liver lobes were fixed in buffered 
formalin solution and embedded in paraffin following consent from donor’s family (Patient 
1) and the donor (Patient 2). Pancreata optimally retrieved during organ donation after brain 
stem death under Research Ethics Committee approval provided non-diabetic control tissue 
for staining of normal adult human islets in situ. Four µm-thick tissue sections were routinely 
stained with haematoxylin and eosin or immunostained with antibodies for endothelial 
(CD31, clone JC70A, Dako, UK) or lymphatic (podoplanin D2-40, clone D240, Ventana, 
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USA) markers using Benchmark Ultra (Ventana, USA) automated slide staining system. Due 
to the limited material available for immunohistochemistry, stains were not performed on 
serial sections. Indirect immunofluorescence was performed in more than 15 separate 
intrahepatic islets in both Patient 1 and Patient 2 in addition to control pancreata using guinea 
pig anti-insulin (Abcam, Cambridge UK), rabbit anti-glucagon (Abcam, Cambridge UK), 
mouse anti-glucagon (Sigma, Gillingham, UK), and mouse anti urocortin-3 (Phoenix, 
Burlingame USA) antibodies. Co-expression of insulin / urocortin-3 and insulin / glucagon 
was confirmed by confocal microscopy Z-stack analysis.  
 
Case reports 
Patient 1 was a 36-year-old female with type 1 diabetes of 27 years’ duration who died 
following a cerebral hemorrhage 13 years after a single percutaneous infusion of isolated 
pancreatic islets pooled from two deceased donors
11
. Islet transplantation was undertaken for 
recurrent life-threatening severe hypoglycemia with poor HbA1c (11.2%)
11
. She attained 
insulin independence three months after transplant, maintaining non-diabetic oral glucose 
tolerance tests with HbA1c consistently <6% without any glucose lowering agents on 
cyclosporin, mycophenolate mofetil and low dose steroid immunosuppression.   
 
Patient 2 was a 34-year-old female with cystic fibrosis and previous lung transplant who 
received a simultaneous liver and kidney transplant with islets from the same deceased donor 
infused into the transplant liver portal vein the following day. Induction was with 
thymoglobulin and ongoing immunosuppression with tacrolimus, mycophenolate and 
prednisolone (continued at a dose of 5 mg daily post-lung transplant without weaning). Over 
the next two years she required three additional islet transplants with basiliximab induction to 
achieve and sustain insulin-independence maintaining non-diabetic HbA1c (4.5%).  
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Three years after the liver transplant, she developed arterial thrombosis of the graft, leading 
to ischemic lesions of intrahepatic bile ducts, cholangitic abscesses and secondary hepatic 
failure. Despite maintained islet graft function (HbA1c 4.6%; basal C-peptide 5 ng/ml), she 
was treated with supplementary low dose exogenous insulin until graft hepatectomy.  
 
Results  
Histological analysis of transplanted islets  
Histological analysis of liver sections from Patient 1 demonstrated engrafted islets within 
portal tracts (Figure 1A) with mild congestive parenchymal changes. Immunostaining for the 
endothelial marker CD31 confirmed that islets were situated within terminal portal vein 
branches (Figure 1B) or inlet venules at the portal/parenchymal interface. Further evidence 
that the islets were situated within vein branches was obtained through absence of 
immunostaining with the lymphatic marker D2-40 (Figure 1C). 
 
Engrafted islets within the terminal portal venules were morphologically identified also in the 
liver explanted from Patient 2 (Figure 1D), which in addition showed evidence of ischemic 
and cholestatic changes in keeping with hepatic artery thrombosis, ductular cholestasis 
indicative of sepsis and mild steatotic changes. There was no evidence of islet fibrosis or 
inflammation. 
 
Differentiation status of transplanted islet β-cells 
Presence of the end-differentiated human islet β-cell / α-cell marker, urocortin-3, was 
confirmed in all insulin-positive and glucagon-positive cells in normal adult islets in situ 
through immunofluorescence co-staining of five non-diabetic control pancreata 
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(Supplementary Figure 1). In contrast, despite co-expression of urocortin-3 in all glucagon-
expressing α-cells, loss of mature β-cell phenotype was confirmed through absent urocortin-3 
staining in all insulin-positive (glucagon-negative) cells within engrafted islets in Patient 1 
(Figure 2A-E) and in Patient 2 (Figure 3A-E).  
 
In addition to loss of end-differentiation, endocrine cell plasticity was demonstrated by cells 
appearing to co-express insulin and glucagon in transplanted islets from both patients (Figure 
2, 3 F-H) with co-localisation within single cells supported by spectral plot (Figure 3I) and Z-
stack confocal microscopy (Supplementary Figure 2). Insulin / glucagon co-expressing cells 
were identified in all examined islets (>10 per donor).  
 
Discussion 
We have demonstrated immunofluorescence staining phenotypes indicating loss of β-cell 
end-differentiation in islets transplanted into the portal vein despite stable engraftment and 
long-term maintenance of normoglycemia. 
 
Metabolic outcomes after intrahepatic islet transplantation continue to improve and this 
procedure can now reproducibly deliver virtually normal overall glycemia in tandem with 
absolute prevention of significant hypoglycemia
12
. Nevertheless, complete normalisation of 
stimulated insulin and C-peptide secretion has remained elusive
3
. Loss of end-differentiated 
β-cell phenotype may provide at least partial explanation for subtle functional impairment, 
despite stable engraftment of sufficient β-cell mass to prevent hyperglycemia.   
 
Urocortin-3 expression has been used to identify mature, fully functional, β-cells during 
pancreas development
5
 and is expressed at approximately equal levels in α- and β-cells in 
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non-diabetic adult human pancreas
13
. Absence of detectable beta-cell urocortin-3 staining in 
all transplanted islets examined in the current study provides evidence for loss of end-
differentiated phenotype despite maintained insulin expression and near-normoglycemia. 
Loss of urocortin-3 has been reported in human β-cells in association with hyperglycemia in 
type 2 diabetes
7,13
. It has been proposed that urocortin-3 loss is an adaptive response to β-cell 
stress / damage, enabling the damaged β-cell to maintain insulin secretion without negative 
feedback inhibition through urocortin-3 mediated δ-cell somatostatin secretion
13
. Further 
mechanistic studies are required to determine whether adaptation of β-cells to acute stress 
evidenced by markers of dedifferentiation including urocortin-3 loss is a direct cause of 
imperfect glucose control through impaired insulin secretion; or whether phenotypic changes 
are a reactive response to beta-cell dysfunction primarily driven by other mechanisms.  
 
Further evidence for a phenotypic shift in intrahepatic transplanted islets was provided by 
identification of insulin and glucagon co-expressing cells. Each hormone appeared to be 
localised to different regions of the cytoplasm without incontrovertible direct overlay. In 
addition to confocal microscopy Z-stack imaging, spectral analysis supported the presence of 
bi-hormonal cells. It has been suggested that β-cell plasticity, leading to cells co-expressing 
insulin and glucagon, may contribute to abnormal glucagon secretion in type 2 diabetes
9
. 
Following islet transplantation glucagon secretion in response to hypoglycaemia remains 
impaired, even following replacement of near-normal pancreatic β-cell mass
14
. Whether β-
cell plasticity, with the presence of cells expressing and secreting both insulin and glucagon, 
plays a role in this residual abnormality of transplanted islet function requires further study.  
 
In the current case reports, β-cell pathology was not associated with decreasing functional β-
cell mass over time or with high glucose. Amyloid deposition has been reported following 
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intrahepatic islet transplantation, in association with failing grafts and elevated blood glucose 
levels
15
. We have previously reported near absence of amyloid deposits around islets from 
Patient 1
16
, in keeping with absence of ongoing β-cell stress due to maintained 
normoglycemia without evidence of attrition in islet function over time.  
 
Loss of end-differentiated phenotype may facilitate β-cell survival during the ex vivo stresses 
associated with islet isolation and culture, in addition to sustained hypoxia following 
engraftment, due to peripheral as opposed to central islet revascularisation as reported by 
ourselves in Patient 1
17
 and by others
18
. We have confirmed that islets remain in or at the 
periphery of the portal tracts at the portal-parenchymal interface. Additional peri- and intra-
islet microvasculature may reflect neovascularisation from hepatic artery
17
. Alternatively, the 
peri-islet microvasculature could correspond to dilated collateral venules associated with 
portal venopathy following intraportal islet infusion.   
 
A limitation of this study is the inability to absolutely quantify numbers of cells which have 
lost end-differentiated β-cell phenotype due to the limited tissue available within these unique 
samples. Nevertheless, absence of urocortin-3 staining provided a reproducible marker of 
altered phenotype seen in all transplanted insulin-positive / glucagon-negative cells evaluated 
in both recipients. In contrast, this phenotype is absent in pancreata from organ donors 
without diabetes, where all insulin-positive cells expressed urocortin-3. Confirmation of 
whether loss of urocortin-3 staining and apparent bi-hormonal cells represent a true 
phenotypic shift will require deeper characterisation of insulin-positive cells, comprising 
staining for expression and sub-cellular localisation of key β-cell transcription factors 
(including Pdx1 and Nkx6.1), examination of secretory granule ultrastructure by transmission 
electron microscopy and transcriptomic analysis following laser capture microdissection
19
.  
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Whether the phenotypic changes confirmed in the current study represent an irreversible 
adaptation to short term reversible peri-transplant stress; or a chronic response to ongoing β-
cell metabolic, inflammatory or immunosuppression-induced stress despite post-
transplantation near normoglycemia remains unclear. Further studies are underway to assess 
whether loss of mature β-cell phenotype reflects an adaptive response to hypoxia
20
.  
 
 
Refinements in islet isolation and culture are ongoing in addition to innovations with the goal 
of fully vascularised engraftment, restoring entirely normal islet mass and function
18
. 
Evaluation of differentiation status through immunostaining co-localisation protocols 
provides a novel tool to assess whether fully mature β-cell phenotype has been maintained 
without dedifferentiation / plasticity following islet and isolated β-cell transplantation.  
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Figure Legends 
 
 
Figure 1. Islets engrafted within recipient liver. A, B, C Liver tissue from Patient 1. A. 
Portal tract with islet within portal venule (thick arrow), interlobular bile duct (white 
arrowhead) and hepatic arteriole profiles (black arrowhead). Hematoxylin & eosin (H&E), 
x200. B. Islet within thin-walled portal venule (thick arrow). Endothelial vascular lining is 
highlighted by CD31 immunostain (thin arrows), x200. C. Islet within inlet venule in a septal 
portal tract. D2-40 immunostain decorates lymphatic endothelium (black arrowheads) but not 
the endothelium of portal vein (PV) or the inlet venule, confirming intravenous localisation 
of the engrafted islet, x200. D. Liver tissue from patient 2. Portal tract with islet within 
portal venule (thick arrow), interlobular bile duct (white arrowhead) and hepatic arteriole 
profiles (black arrowheads). There is ductular cholestasis (*) and the periportal parenchyma 
shows hepatocellular cholestasis and mild macrovesicular steatosis, H&E x200. 
 
Figure 2: Changes in β-cell phenotype in patient 1 following intraportal islet 
transplantation. Panel A demonstrates typical staining for insulin/glucagon/urocortin-3 in an 
islet from patient 1. Boxed region in A shows area magnified in B-E. Islet β-cells stained 
positive for insulin but all lacked urocortin-3 (UCN3) co-expression (circle indicates 
insulin
+
/UCN3
-
 cells). All glucagon
+
 α-cells maintain UCN3 co-expression. Scale bars 
represent 20 µm in A and 10 µm in B-E. Panels F-H show islet cells (indicated by arrows) 
co-expressing insulin and glucagon. Scale bars represent 20 µm in F-H. Images 
representative of >10 transplanted islets.  
 
Figure 3: Changes in β-cell phenotype in patient 2 following intra-portal islet 
transplantation. Panel A demonstrates typical staining for insulin/glucagon/UCN3 in an islet 
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from patient 2. Boxed region in A shows area magnified in B-E. Islet β-cells stained positive 
for insulin but lacked UCN3 co-expression (circle indicates insulin
+
/UCN3
-
 cells). Glucagon
+
 
α-cells maintain UCN3 co-expression. Scale bars represent 20 µm in A and 10 µm in B-E. 
Panels F-H show islet cells (indicated by arrows) co-expressing insulin and glucagon. Scale 
bars represent 20 µm in F-H. Images representative of >10 islets. Panel I shows a Spectral 
Plot (NIS Elements AR software) obtained from the cell circled in F-H confirming insulin 
and glucagon co-staining at the area indicated by the arrow in the microscopy images and line 
on the graph.  
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Supporting Information 
Additional Supporting Information may be found in the online version of this article. 
 
Figure S1: Urocortin-3 expression in normal human pancreas. Panel A demonstrates 
typical staining for insulin/glucagon/UCN3 in a representative islet within a non-diabetic 
deceased organ donor pancreas. All insulin
+
 and glucagon
+
 cells co-express UCN3. Scale 
bars represent 50 µm.  
 
Figure S2: Z-stack confocal microscopy imaging of biohormonal cell in patient 2. Series 
of Z-stack images, showing 2 µm thick sections through an insulin / glucagon co-expressing 
cell. Scale bar: 10 µm.  
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